An Option for COVID-19 Positive Patients: Monoclonal Antibody Treatment

Understanding Your Risks of COVID-19

- The Center for Disease Control surveillance data reports that individuals over 50 represent only 35% of COVID patients in the US, but unfortunately represent 95% of the deaths.

Understanding the Risk of COVID-19 and the FDA EUA

- In consideration of these elevated risks, the Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for the use of monoclonal antibody therapy in “high-risk” patients with COVID-19.
  - High risk is defined as having any of the following:
    - 65 years or older
    - Have a body mass index (BMI) ≥35
    - Have chronic kidney disease
    - Have diabetes
    - Have immunosuppressive disease
    - Are currently receiving immunosuppressive treatment
  - Are ≥ 55 years of age AND have
    - Cardiovascular disease, OR
    - High blood pressure, OR
    - COPD, Emphysema, or other lung diseases
  - Are 12-17 years of age AND have
    - BMI ≥ 85th percentile for their age and gender OR
    - Sickle cell disease OR heart disease OR neurodevelopment disorders OR asthma

Understanding Monoclonal Antibody Treatment

- Monoclonal antibody therapy directly neutralizes the virus.
- In clinical trials, those who received this treatment soon after diagnosis experienced fewer symptoms and hospitalizations.
- It is important to receive the treatment as soon as possible following a positive test result and within 10 days of symptom onset.
- The treatment is a IV therapy administered in an outpatient or hospital setting.
- It takes up to an hour to administer, followed by an hour of observation. Afterwards, you are sent home, continue isolation.

Ask Your Health Care Professional

- Your Health Care Provider can provide you more information about your treatment options and any additional requirements.
- Most importantly, wear your mask, stay at home, and isolate after treatment.

For more information about COVID therapies, please visit: https://CombatCOVID.HHS.gov